| 1000 | Humans (MeSH) |
| 973 | Aged (MeSH) |
| 841 | Pandemics (MeSH) |
| 835 | Male (MeSH) |
| 810 | Female (MeSH) |
| 774 | Middle Aged (MeSH) |
| 577 | Betacoronavirus (MeSH) |
| 532 | Adult (MeSH) |
| 443 | Pneumonia, Viral (epidemiology) |
| 443 | Coronavirus Infections (epidemiology) |
| 398 | Aged, 80 and over (MeSH) |
| 274 | Coronavirus Infections (diagnosis) |
| 269 | Young Adult (MeSH) |
| 264 | Retrospective Studies (MeSH) |
| 252 | Pneumonia, Viral (diagnosis) |
| 220 | Pneumonia, Viral (virology) |
| 218 | Coronavirus Infections (virology) |
| 214 | Pneumonia, Viral (complications) |
| 214 | Coronavirus Infections (complications) |
| 210 | Adolescent (MeSH) |
| 197 | Pneumonia, Viral (mortality) |
| 197 | Coronavirus Infections (mortality) |
| 164 | Pneumonia, Viral (therapy) |
| 164 | Coronavirus Infections (therapy) |
| 151 | Risk Factors (MeSH) |
| 136 | Pandemics (prevention & control) |
| 130 | Coronavirus Infections (prevention & control) |
| 129 | Pneumonia, Viral (prevention & control) |
| 126 | Betacoronavirus (isolation & purification) |
| 122 | Severity of Illness Index (MeSH) |
| 105 | Child (MeSH) |
| 103 | Comorbidity (MeSH) |
| 97 | Treatment Outcome (MeSH) |
| 88 | Pneumonia, Viral (blood) |
| 88 | Coronavirus Infections (blood) |
| 86 | Coronavirus Infections (drug therapy) |
| 83 | Prognosis (MeSH) |
| 78 | Hospitalization (MeSH) |
| 77 | Child, Preschool (MeSH) |
| 76 | Betacoronavirus (pathogenicity) |
| 76 | Age Factors (MeSH) |
| 75 | Pneumonia, Viral (transmission) |
| 75 | Pneumonia, Viral (physiopathology) |
| 75 | Coronavirus Infections (physiopathology) |
| 74 | Coronavirus Infections (transmission) |
| 72 | Cross-Sectional Studies (MeSH) |
| 69 | Pneumonia, Viral (drug therapy) |
| 69 | China (epidemiology) |
| 68 | Pneumonia, Viral (pathology) |
| 68 | Pneumonia, Viral (immunology) |
| 68 | Coronavirus Infections (pathology) |
| 68 | Coronavirus Infections (immunology) |
| 66 | Pneumonia, Viral (psychology) |
| 66 | Coronavirus Infections (psychology) |
| 63 | Infant (MeSH) |
| 63 | Cohort Studies (MeSH) |
| 62 | Pneumonia, Viral (diagnostic imaging) |
| 60 | Prospective Studies (MeSH) |
| 59 | Coronavirus Infections (diagnostic imaging) |
| 58 | Tomography, X-Ray Computed (MeSH) |
| 55 | Risk Assessment (MeSH) |
| 54 | Lung (diagnostic imaging) |
| 53 | Surveys and Questionnaires (MeSH) |
| 51 | Hospitalization (statistics & numerical data) |
| 50 | Intensive Care Units (MeSH) |
| 50 | Clinical Laboratory Techniques (MeSH) |
| 49 | Betacoronavirus (genetics) |
| 48 | Time Factors (MeSH) |
| 48 | Italy (epidemiology) |
| 48 | Hospital Mortality (MeSH) |
| 47 | Incidence (MeSH) |
| 44 | Betacoronavirus (immunology) |
| 43 | Disease Progression (MeSH) |
| 40 | Pneumonia, Viral (MeSH) |
| 40 | Infant, Newborn (MeSH) |
| 39 | Coronavirus Infections (MeSH) |
| 37 | United States (epidemiology) |
| 34 | Follow-Up Studies (MeSH) |
| 33 | Sex Factors (MeSH) |
| 33 | Antibodies, Viral (blood) |
| 32 | Clinical Laboratory Techniques (methods) |
| 31 | Biomarkers (blood) |
| 30 | Prevalence (MeSH) |
| 29 | Critical Illness (MeSH) |
| 27 | Survival Analysis (MeSH) |
| 27 | China (MeSH) |
| 27 | Case-Control Studies (MeSH) |
| 27 | Antiviral Agents (therapeutic use) |
| 26 | Sensitivity and Specificity (MeSH) |
| 25 | Respiration, Artificial (MeSH) |
| 25 | Logistic Models (MeSH) |
| 25 | Hydroxychloroquine (therapeutic use) |
| 24 | Tomography, X-Ray Computed (methods) |
| 23 | Age Distribution (MeSH) |
| 22 | Italy (MeSH) |
| 21 | Proportional Hazards Models (MeSH) |
| 21 | Pandemics (statistics & numerical data) |
| 21 | Lung (pathology) |
| 20 | ROC Curve (MeSH) |
| 20 | Immunoglobulin G (blood) |
| 20 | C-Reactive Protein (metabolism) |
| 20 | C-Reactive Protein (analysis) |
| 20 | Anti-Bacterial Agents (therapeutic use) |
| 19 | Quarantine (MeSH) |
| 19 | Predictive Value of Tests (MeSH) |
| 19 | Odds Ratio (MeSH) |
| 19 | Intensive Care Units (statistics & numerical data) |
| 19 | Disease Outbreaks (MeSH) |
| 18 | Fatal Outcome (MeSH) |
| 18 | Diabetes Mellitus (epidemiology) |
| 18 | Anxiety (epidemiology) |
| 17 | Lymphocyte Count (MeSH) |
| 17 | Length of Stay (statistics & numerical data) |
| 16 | Spain (epidemiology) |
| 16 | Social Isolation (MeSH) |
| 16 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 16 | Respiratory Distress Syndrome, Adult (virology) |
| 16 | Lung (virology) |
| 16 | Length of Stay (MeSH) |
| 15 | United Kingdom (MeSH) |
| 15 | Survival Rate (MeSH) |
| 15 | Registries (MeSH) |
| 15 | Real-Time Polymerase Chain Reaction (MeSH) |
| 15 | Infection Control (methods) |
| 15 | Health Status Disparities (MeSH) |
| 15 | Drug Combinations (MeSH) |
| 15 | Contact Tracing (MeSH) |
| 15 | Brazil (epidemiology) |
| 15 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 14 | United Kingdom (epidemiology) |
| 14 | Ritonavir (therapeutic use) |
| 14 | Respiratory Insufficiency (therapy) |
| 14 | Reproducibility of Results (MeSH) |
| 14 | Nursing Homes (MeSH) |
| 14 | Lopinavir (therapeutic use) |
| 14 | Hospital Mortality (trends) |
| 14 | Health Knowledge, Attitudes, Practice (MeSH) |
| 14 | Coronavirus (MeSH) |
| 14 | Betacoronavirus (physiology) |
| 14 | Betacoronavirus (drug effects) |
| 14 | Azithromycin (therapeutic use) |
| 14 | Anticoagulants (therapeutic use) |
| 13 | United States (MeSH) |
| 13 | Symptom Assessment (MeSH) |
| 13 | Stroke (epidemiology) |
| 13 | Socioeconomic Factors (MeSH) |
| 13 | Pneumonia, Viral (ethnology) |
| 13 | Neoplasms (epidemiology) |
| 13 | Mortality (MeSH) |
| 13 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 13 | Hypertension (epidemiology) |
| 13 | Germany (epidemiology) |
| 13 | France (epidemiology) |
| 13 | Diagnosis, Differential (MeSH) |
| 13 | Coronavirus Infections (metabolism) |
| 13 | Coronavirus Infections (ethnology) |
| 13 | Cause of Death (MeSH) |
| 13 | Anxiety (psychology) |
| 12 | Stroke (therapy) |
| 12 | Seroepidemiologic Studies (MeSH) |
| 12 | Risk Assessment (methods) |
| 12 | Respiratory Distress Syndrome, Adult (therapy) |
| 12 | Respiratory Distress Syndrome, Adult (etiology) |
| 12 | Respiration, Artificial (statistics & numerical data) |
| 12 | Respiration, Artificial (methods) |
| 12 | Republic of Korea (epidemiology) |
| 12 | RNA, Viral (analysis) |
| 12 | New York City (epidemiology) |
| 12 | Leukocyte Count (MeSH) |
| 12 | Hypertension (complications) |
| 12 | Hospitals, University (MeSH) |
| 12 | Health Personnel (MeSH) |
| 12 | Dyspnea (etiology) |
| 12 | Clinical Laboratory Techniques (statistics & numerical data) |
| 11 | Viral Load (MeSH) |
| 11 | Time-to-Treatment (MeSH) |
| 11 | Telemedicine (MeSH) |
| 11 | Spain (MeSH) |
| 11 | Sex Distribution (MeSH) |
| 11 | Risk (MeSH) |
| 11 | Quarantine (psychology) |
| 11 | Pneumonia, Viral (metabolism) |
| 11 | Pneumonia, Viral (etiology) |
| 11 | Nasopharynx (virology) |
| 11 | Models, Statistical (MeSH) |
| 11 | Host-Pathogen Interactions (MeSH) |
| 11 | Fibrin Fibrinogen Degradation Products (analysis) |
| 11 | Exercise (MeSH) |
| 11 | Depression (epidemiology) |
| 11 | Critical Care (MeSH) |
| 11 | Communicable Disease Control (methods) |
| 11 | Body Mass Index (MeSH) |
| 11 | Animals (MeSH) |
| 10 | Tertiary Care Centers (MeSH) |
| 10 | Stroke (diagnosis) |
| 10 | Spike Glycoprotein, Coronavirus (immunology) |
| 10 | Social Isolation (psychology) |
| 10 | Respiratory Insufficiency (etiology) |
| 10 | Pneumonia, Viral (genetics) |
| 10 | Neutrophils (MeSH) |
| 10 | Multivariate Analysis (MeSH) |
| 10 | Longitudinal Studies (MeSH) |
| 10 | Internet (MeSH) |
| 10 | Health Personnel (statistics & numerical data) |
| 10 | Emergency Service, Hospital (statistics & numerical data) |
| 10 | Coronavirus Infections (genetics) |
| 10 | Cluster Analysis (MeSH) |
| 10 | Cardiovascular Diseases (epidemiology) |
| 10 | Area Under Curve (MeSH) |
| 9 | Stress, Psychological (epidemiology) |
| 9 | Respiration, Artificial (adverse effects) |
| 9 | Radiography, Thoracic (MeSH) |
| 9 | Quality of Life (MeSH) |
| 9 | Polymerase Chain Reaction (MeSH) |
| 9 | Mental Health (MeSH) |
| 9 | Hospitals (MeSH) |
| 9 | Health Behavior (MeSH) |
| 9 | Fever (etiology) |
| 9 | Ferritins (blood) |
| 9 | Family (MeSH) |
| 9 | Disease Transmission, Infectious (prevention & control) |
| 9 | Critical Care (methods) |
| 9 | Australia (epidemiology) |
| 9 | Acute Disease (MeSH) |
| 8 | Social Media (MeSH) |
| 8 | RNA, Viral (isolation & purification) |
| 8 | Public Health (MeSH) |
| 8 | Practice Guidelines as Topic (MeSH) |
| 8 | Patient Safety (MeSH) |
| 8 | Outcome Assessment, Health Care (MeSH) |
| 8 | Neoplasms (therapy) |
| 8 | Mass Screening (methods) |
| 8 | Kidney Failure, Chronic (therapy) |
| 8 | Interleukin-6 (blood) |
| 8 | Infection Control (organization & administration) |
| 8 | Glucocorticoids (therapeutic use) |
| 8 | France (MeSH) |
| 8 | Fever (virology) |
| 8 | Ethnic Groups (statistics & numerical data) |
| 8 | Emergency Service, Hospital (MeSH) |
| 8 | Drug Therapy, Combination (MeSH) |
| 8 | Depression (psychology) |
| 8 | Cytokines (blood) |
| 8 | Asymptomatic Diseases (MeSH) |
| 8 | Antiviral Agents (adverse effects) |
| 8 | Acute Kidney Injury (epidemiology) |
| 7 | Vulnerable Populations (MeSH) |
| 7 | Travel (MeSH) |
| 7 | Thrombosis (virology) |
| 7 | Telemedicine (methods) |
| 7 | Social Distance (MeSH) |
| 7 | Serologic Tests (methods) |
| 7 | Renal Dialysis (MeSH) |
| 7 | Randomized Controlled Trials as Topic (MeSH) |
| 7 | Quarantine (methods) |
| 7 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
| 7 | Prone Position (MeSH) |
| 7 | Pregnancy (MeSH) |
| 7 | Population Surveillance (MeSH) |
| 7 | Pneumonia, Viral (nursing) |
| 7 | Platelet Count (MeSH) |
| 7 | Patient Selection (MeSH) |
| 7 | Patient Isolation (MeSH) |
| 7 | Nursing Homes (statistics & numerical data) |
| 7 | Liver Diseases (epidemiology) |
| 7 | Kaplan-Meier Estimate (MeSH) |
| 7 | Japan (MeSH) |
| 7 | Inpatients (MeSH) |
| 7 | Host Microbial Interactions (MeSH) |
| 7 | Health Status (MeSH) |
| 7 | Health Policy (MeSH) |
| 7 | Hand Disinfection (MeSH) |
| 7 | Geriatric Assessment (MeSH) |
| 7 | Fibrin Fibrinogen Degradation Products (metabolism) |
| 7 | England (epidemiology) |
| 7 | Early Diagnosis (MeSH) |
| 7 | Drug Administration Schedule (MeSH) |
| 7 | Delivery of Health Care (MeSH) |
| 7 | Databases, Factual (MeSH) |
| 7 | Critical Illness (epidemiology) |
| 7 | Coronavirus Infections (nursing) |
| 7 | Coronavirus Infections (etiology) |
| 7 | Coronavirus Infections (economics) |
| 7 | Combined Modality Therapy (MeSH) |
| 7 | Chronic Disease (MeSH) |
| 7 | Antimalarials (therapeutic use) |
| 7 | Algorithms (MeSH) |
| 7 | Aging (MeSH) |
| 7 | Adaptation, Psychological (MeSH) |
| 6 | Triage (methods) |
| 6 | Thrombosis (etiology) |
| 6 | Survival Rate (trends) |
| 6 | Social Support (MeSH) |
| 6 | Severe Acute Respiratory Syndrome (epidemiology) |
| 6 | Seroconversion (MeSH) |
| 6 | Sampling Studies (MeSH) |
| 6 | Respiratory Insufficiency (virology) |
| 6 | Respiratory Distress Syndrome, Adult (mortality) |
| 6 | Research Design (MeSH) |
| 6 | Radiography, Thoracic (methods) |
| 6 | RNA, Viral (genetics) |
| 6 | Propensity Score (MeSH) |
| 6 | Pneumonia, Viral (rehabilitation) |
| 6 | Pneumonia, Viral (economics) |
| 6 | Personal Protective Equipment (MeSH) |
| 6 | Peptidyl-Dipeptidase A (genetics) |
| 6 | Patient Discharge (statistics & numerical data) |
| 6 | Patient Discharge (MeSH) |
| 6 | Patient Admission (statistics & numerical data) |
| 6 | Pandemics (economics) |
| 6 | Oxygen Inhalation Therapy (methods) |
| 6 | Oxygen Inhalation Therapy (MeSH) |
| 6 | Nursing Homes (organization & administration) |
| 6 | Noninvasive Ventilation (methods) |
| 6 | New York City (MeSH) |
| 6 | Models, Theoretical (MeSH) |
| 6 | Machine Learning (MeSH) |
| 6 | Loneliness (MeSH) |
| 6 | L-Lactate Dehydrogenase (blood) |
| 6 | India (epidemiology) |
| 6 | Immunoglobulin M (blood) |
| 6 | Hypoxia (etiology) |
| 6 | Heart Diseases (epidemiology) |
| 6 | Health Personnel (psychology) |
| 6 | Germany (MeSH) |
| 6 | Feasibility Studies (MeSH) |
| 6 | Ethnic Groups (MeSH) |
| 6 | Emergencies (MeSH) |
| 6 | Cytokines (immunology) |
| 6 | Cross Infection (prevention & control) |
| 6 | Critical Illness (mortality) |
| 6 | Cough (virology) |
| 6 | Coronavirus Infections (rehabilitation) |
| 6 | Computer Simulation (MeSH) |
| 6 | Communication (MeSH) |
| 6 | Clinical Decision-Making (MeSH) |
| 6 | Attitude to Health (MeSH) |
| 6 | Asymptomatic Infections (epidemiology) |
| 6 | Antibodies, Viral (immunology) |
| 6 | African Americans (MeSH) |
| 6 | Adrenal Cortex Hormones (therapeutic use) |
| 5 | Virus Shedding (MeSH) |
| 5 | Ultrasonography (MeSH) |
| 5 | Thrombolytic Therapy (MeSH) |
| 5 | Tertiary Care Centers (statistics & numerical data) |
| 5 | Telephone (MeSH) |
| 5 | Stroke (complications) |
| 5 | Spike Glycoprotein, Coronavirus (genetics) |
| 5 | Smoking (epidemiology) |
| 5 | Serologic Tests (MeSH) |
| 5 | Self Report (MeSH) |
| 5 | Ritonavir (adverse effects) |
| 5 | Respiratory Therapy (methods) |
| 5 | Respiratory Function Tests (MeSH) |
| 5 | Renal Insufficiency, Chronic (epidemiology) |
| 5 | Renal Dialysis (methods) |
| 5 | Pulmonary Embolism (virology) |
| 5 | Pulmonary Disease, Chronic Obstructive (complications) |
| 5 | Protective Factors (MeSH) |
| 5 | Postoperative Complications (epidemiology) |
| 5 | Population Surveillance (methods) |
| 5 | Pilot Projects (MeSH) |
| 5 | Peptidyl-Dipeptidase A (metabolism) |
| 5 | Patient Admission (trends) |
| 5 | Occupational Diseases (epidemiology) |
| 5 | Nucleocapsid Proteins (immunology) |
| 5 | Needs Assessment (MeSH) |
| 5 | Mental Health (statistics & numerical data) |
| 5 | Lymphocytes (MeSH) |
| 5 | Lopinavir (adverse effects) |
| 5 | Long-Term Care (MeSH) |
| 5 | Loneliness (psychology) |
| 5 | Israel (epidemiology) |
| 5 | Interpersonal Relations (MeSH) |
| 5 | Inflammation (immunology) |
| 5 | Infection Control (MeSH) |
| 5 | Hypoxia (therapy) |
| 5 | Hypertension (drug therapy) |
| 5 | Hydroxychloroquine (adverse effects) |
| 5 | Hospitalization (trends) |
| 5 | Homes for the Aged (statistics & numerical data) |
| 5 | Homes for the Aged (MeSH) |
| 5 | Heart Failure (epidemiology) |
| 5 | Health Services Needs and Demand (MeSH) |
| 5 | Health Services Accessibility (MeSH) |
| 5 | Global Health (MeSH) |
| 5 | Forecasting (MeSH) |
| 5 | Fever (diagnosis) |
| 5 | Feeding Behavior (MeSH) |
| 5 | Family Characteristics (MeSH) |
| 5 | European Continental Ancestry Group (statistics & numerical data) |
| 5 | Europe (epidemiology) |
| 5 | Enzyme Inhibitors (therapeutic use) |
| 5 | Dyspnea (diagnosis) |
| 5 | Disease Outbreaks (statistics & numerical data) |
| 5 | Diabetes Mellitus, Type 2 (epidemiology) |
| 5 | Diabetes Mellitus, Type 2 (complications) |
| 5 | Demography (MeSH) |
| 5 | Cytokine Release Syndrome (immunology) |
| 5 | Critical Care (statistics & numerical data) |
| 5 | Cough (etiology) |
| 5 | Cough (diagnosis) |
| 5 | Communicable Disease Control (organization & administration) |
| 5 | Coinfection (epidemiology) |
| 5 | CD8-Positive T-Lymphocytes (immunology) |
| 5 | Autopsy (MeSH) |
| 5 | Antiviral Agents (administration & dosage) |
| 5 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 5 | Anti-Inflammatory Agents (therapeutic use) |
| 5 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 5 | Aging (physiology) |
| 5 | African Americans (statistics & numerical data) |
| 5 | Acute Kidney Injury (diagnosis) |
| 5 | APACHE (MeSH) |
| 4 | Vitamin D (blood) |
| 4 | Vitamin D (analogs & derivatives) |
| 4 | Utah (epidemiology) |
| 4 | Urban Population (MeSH) |
| 4 | Uncertainty (MeSH) |
| 4 | Ultrasonography (methods) |
| 4 | Turkey (epidemiology) |
| 4 | Troponin I (blood) |
| 4 | Thrombosis (pathology) |
| 4 | Thrombosis (complications) |
| 4 | Thrombolytic Therapy (methods) |
| 4 | Thrombectomy (MeSH) |
| 4 | T-Lymphocytes (virology) |
| 4 | Symptom Assessment (statistics & numerical data) |
| 4 | Symptom Assessment (methods) |
| 4 | Sweden (MeSH) |
| 4 | Stroke Volume (MeSH) |
| 4 | Stroke (virology) |
| 4 | Stroke (etiology) |
| 4 | Smoking (adverse effects) |
| 4 | Skilled Nursing Facilities (MeSH) |
| 4 | Severe Acute Respiratory Syndrome (virology) |
| 4 | Severe Acute Respiratory Syndrome (MeSH) |
| 4 | ST Elevation Myocardial Infarction (therapy) |
| 4 | Ritonavir (administration & dosage) |
| 4 | Respiratory Insufficiency (physiopathology) |
| 4 | Respiratory Insufficiency (diagnosis) |
| 4 | Respiratory Distress Syndrome, Adult (physiopathology) |
| 4 | Respiratory Distress Syndrome, Adult (epidemiology) |
| 4 | Republic of Korea (MeSH) |
| 4 | Regression Analysis (MeSH) |
| 4 | Referral and Consultation (statistics & numerical data) |
| 4 | Referral and Consultation (MeSH) |
| 4 | Recurrence (MeSH) |
| 4 | Real-Time Polymerase Chain Reaction (methods) |
| 4 | RNA, Viral (blood) |
| 4 | Quarantine (statistics & numerical data) |
| 4 | Pulmonary Embolism (diagnostic imaging) |
| 4 | Public Opinion (MeSH) |
| 4 | Public Health (methods) |
| 4 | Procalcitonin (blood) |
| 4 | Population Density (MeSH) |
| 4 | Personal Protective Equipment (supply & distribution) |
| 4 | Patient Care Team (organization & administration) |
| 4 | Palliative Care (statistics & numerical data) |
| 4 | Outcome and Process Assessment, Health Care (MeSH) |
| 4 | Oceanic Ancestry Group (statistics & numerical data) |
| 4 | Observational Studies as Topic (MeSH) |
| 4 | Obesity (epidemiology) |
| 4 | Obesity (complications) |
| 4 | Nutritional Status (MeSH) |
| 4 | Nomograms (MeSH) |
| 4 | New York (epidemiology) |
| 4 | Netherlands (epidemiology) |
| 4 | Neoplasms (pathology) |
| 4 | Neoplasms (complications) |
| 4 | Mutation (MeSH) |
| 4 | Multimorbidity (MeSH) |
| 4 | Mortality (trends) |
| 4 | Minority Groups (statistics & numerical data) |
| 4 | Methylprednisolone (therapeutic use) |
| 4 | Methylprednisolone (administration & dosage) |
| 4 | Mental Disorders (epidemiology) |
| 4 | Mass Screening (MeSH) |
| 4 | Mass Media (MeSH) |
| 4 | Masks (MeSH) |
| 4 | Magnetic Resonance Imaging (MeSH) |
| 4 | Lymphopenia (epidemiology) |
| 4 | Lung Neoplasms (complications) |
| 4 | Lung (physiopathology) |
| 4 | Lopinavir (administration & dosage) |
| 4 | Kidney Failure, Chronic (epidemiology) |
| 4 | Japan (epidemiology) |
| 4 | Iran (MeSH) |
| 4 | Interleukin-6 (metabolism) |
| 4 | Inpatients (statistics & numerical data) |
| 4 | Influenza, Human (epidemiology) |
| 4 | Inflammation (virology) |
| 4 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
| 4 | Income (MeSH) |
| 4 | Immunosuppressive Agents (therapeutic use) |
| 4 | Immunization, Passive (methods) |
| 4 | Hypertension (diagnosis) |
| 4 | Hospitals, Community (MeSH) |
| 4 | Heparin, Low-Molecular-Weight (therapeutic use) |
| 4 | Heart Diseases (etiology) |
